Search Browse Earnings

Oruka Therapeutics, Inc.

Nasdaq:ORKA

Pharmaceutical Preparations·MENLO PARK, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

CEO

Klein Lawrence Otto

Revenue

$0

FY 2023

Adj. EBITDA

-$88.1M

FY 2024

Net Income

-$83.7M

FY 2024

EPS (Diluted)

-$3.87

FY 2024

Stock Price

$33.69

+0.5%

2026-03-10

52W Range

$5.49 – $36.53

P/E Ratio

-8.7x

Market Cap

$1.6B

Cash

$61.6M

FY 2024

Total Debt

—

Net Cash

$61.6M

FY 2023

Enterprise Value

$1.6B

Debt / EBITDA

0.7x

FY 2023

EV / EBITDA

-17.8x

Employees

—